Sarepta Therapeutics reported second quarter 2026 financial results on August 5, 2026. Net product revenues totaled $328.7 million, comprising $230.6 million from PMO therapies and $98.1 million from ELEVIDYS. The company achieved GAAP operating income of $13.3 million and non-GAAP operating income of $86.5 million. Total revenues decreased 34% to $401.3 million, primarily due to lower ELEVIDYS sales volume following an updated label restricting treatment to ambulatory patients and the absence of a prior-year Roche milestone payment. Sarepta narrowed its full-year 2026 revenue guidance to $1.2-$1.3 billion from a previous range of $1.2-$1.4 billion, while reducing combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million. The company also recorded a $39.0 million litigation contingency charge related to patent disputes. Michael Severino, MD, began his tenure as CEO on July 28, 2026, succeeding Doug Ingram. Sarepta Therapeutics operates in the biopharmaceutical industry, specializing in precision genetic medicines for rare diseases.

Sarepta Therapeutics, Inc. announced the appointment of Michael Severino, M.D., as Chief Executive Officer, effective July 28, 2026. Dr. Severino succeeds Douglas Ingram, who is retiring and will serve as a consultant to the company to ensure a smooth transition until December 31, 2026. Dr. Severino's compensation package includes an annual base salary of $1,180,000 and a sign-on equity grant with a value of approximately $35,000,000. Sarepta Therapeutics, Inc. is a biotechnology company that develops precision genetic medicine for rare diseases.